Galapagos and Arthrogen enter target discovery alliance

“This collaboration with Arthrogen again demonstrates the power of our SilenceSelect target discovery engine,” said Onno van de Stolpe, Chief Executive Officer of Galapagos.  “We look forward to working with Arthrogen to identify successful targets for their rheumatoid arthritis gene therapy programs.”
“Arthrogen strongly believes that the dedicated target discovery technologies from Galapagos will increase the quantity and the quality of Arthrogen’s product pipeline, and will accelerate Arthrogen’s programs to bring innovative local gene therapy products for rheumatoid arthritis to the clinic and the market,” said Willem van Oort, Chief Executive Officer of Arthrogen.
About SilenceSelect discovery technology
The SilenceSelect target discovery platform is based on adenoviruses that efficiently introduce human gene sequences into a wide variety of human cells to knock-down specific proteins.  High-throughput assays that represent a selected human disease state are then used to functionally select for those proteins that have a causative effect in those models of human disease.  After rigorous validation of these protein targets, they form the basis for the development of novel drugs.